World ADC Europe | In-Person and Digital Options Available

8:00 am Registration Open

8:50 am Chairperson’s Opening Remarks

Dario Neri Chief Executive Officer, Philogen

Reviewing Recent Breakthroughs & Thinking Strategically About the ADC Landscape

9:00 am Bringing Mirvetuximab Soravtansine, an FR-alpha Directed ADC, to Patients with Ovarian Cancer

Mimi Huizinga SVP, Head of Medical Affairs, ImmunoGen

Synopsis

Discussing efficacy and safety of MIRV in FR-alpha high, platinum resistant ovarian cancer
Outlining the evolution of the companion diagnostics and impacts on trials
Sharing information about on-going trials and next steps

9:30 am Industry Leaders Panel Discussion – Reviewing the Last Year & Creating Strategies to Further Develop ADCs Through 2022

Shweta Jain Senior Medical Director, Seagen
Dario Neri Chief Executive Officer, Philogen
Mimi Huizinga SVP, Head of Medical Affairs, ImmunoGen
Gilles Gallant SVP Global Head, Oncology Department, Oncology R&D, Daiichi Sankyo

Synopsis

Reviewing how breakthroughs in 2021 are shaping the ADC industry
What decision are industry pioneers making to ensure continued progress within the ADC space (technical and business/partnership decisions)?
Outlining the biggest challenges that ADC drug developers are facing in taking drugs from the bench to bedside
Discussing methods to bring ADCs to earlier-line treatment

10:15 am Structured Networking

Synopsis

This session is a great opportunity to introduce yourself to the attendees that you would like to have more in depth conversations with. This session is the ideal opportunity to get back to face-to-face interaction with many of the brightest minds working in the ADC field and establish meaningful business relationships.

AM: Discovery Stream Chair: Philip Howard, Chief Scientific Officer, Spirogen

Harnessing Novel Linker Technologies to Widen the Therapeutic Index

11.15 How to Successfully Design & Develop Your Antibody-Drug Conjugate

Exploring how ADC linkers represent more than a bridge between the antibody and cytotoxin, offering several advantages including optimisation of drug loading (DAR), and improvements in therapeutic indices;
Identifying the best combination of antibody, linker and drug is a challenge overcome by applying stage-specific evaluation criteria to de-risk ADC candidate selection with the best chance of clinical success;
Understanding how to accelerate and construct appropriate ADC candidate matrices by combining different conjugation approaches, linker architectures, cytotoxins and release mechanisms through real-world case studies is presented.

Mark Frigerio, PhD. Vice President Design and Development, Abzena

11.45 *Virtual* Understand the Effect of Conjugation Site & Technique on the Stability & Pharmacokinetics of Antibody-Drug Conjugates

Review the characterisation of ADCs that were conjugated by different conjugation methods to different conjugation positions by multiple in vitro assays
Evaluate ADCs in vivo for conjugate stability and pharmacokinetic (PK) behavior in transgenic Tg276 mice
Review the ADC variants regarding in vitro assay and in vivo PK properties

Christian Schroeter, Associate Director, ADCs & Targeted NBE Therapeutics, Merck Healthcare Business

12.15 Review the dynamic technology landscape in bioconjugation and discuss associated challenges for the discovery and development of bioconjugates

Explore how a toolbox approach facilitates finding suitable combinations of conjugation technology, linker and payload
Present how an integrated solution ranging from bioconjugate design to lead candidate enables de-risking and streamlined transfer to clinical manufacturing

Nina Hentzen, Senior Scientist R&D Bioconjugates, Lonza

AM: Translational Stream Chair: Greg Thurber, Associate Chair & Associate Professor of Chemical Engineering, University of Michigan

Understanding the Optimal PK Property of Your ADC to Reduce Associated Toxicities

11.15 SMARTag^® ADC Technology Delivers on the Fundamentals to Support Best-In-Class Asset Development

The SMARTag® platform is a clinical-stage technology with structural flexibility afforded by its use of site-specific conjugation with multiple linkers, warheads, and conjugation site options enabling the production of optimally designed, best-in-class ADCs.
We emphasize drug-conjugate stability, which begins with our stable C-C bond forming HIPS conjugation chemistry paired with proprietary noncleavable or tandem-cleavage linkers, to keep the payload on the antibody for improved delivery to tumors with reduced shedding into the circulation.
Our toolkit also enables the production of high DAR ADCs (up to 7-8 warheads/antibody). In this context, we pair optimized conjugation sites with hydrophilic branched linkers to generate ADCs with enhanced biophysical properties and an expanded therapeutic index.

Ayo Ogunkoya, Ph.D. Sr. Research Scientist, Chemical Biology, Catalent Biologics

11.45 XB002: Model-Based Dose Selection for a Novel Anti-Tissue Factor ADC With a ZLA Payload for the Treatment of Solid Tumours

Review how efficacy data from Pharmacology tumour models in mice and PK data from monkeys were used to predict XB002 human PK and estimate human efficacious dose
Understand how nonclinical safety in cynomolgus monkeys demonstrated adequate safety margins for the range of doses explored in the FTIH study
Assess how the PK model was fitted to the human PK from the FTIH dose escalation phase to refine dose predictions

Raffaella Faggioni, Vice President, Clinical & Translational Pharmacology, Exelixis

12.15 Identifying the Causes of Toxicities & Harnessing Approaches to Reduce On & Off-Target Toxicities

Discussing what is known about the causes of on and off-target toxicities
Exploring how to modulate the PK property of your ADC to reduce toxicity, and evaluating how this differs with different payloads
Understanding how translatable preclinical toxicities are into the clinic

Greg Thurber, Associate Chair & Associate Professor of Chemical Engineering, University of Michigan

AM: Clinical Stream Chair: Heather Van Epps, Director, Research Early-Stage Clinical Programs, Seagen

Overviewing the Clinical Landscape & Recent Clinical Developments

11.15 *Virtual* Antibody Drug Conjugate DeveProviding a Clinical Update of an EGFR Targeted ADC MRG003

Review the ADC landscape in China
Investigate potent anti-tumour activity in preclinical studies
Demonstrate manageable safety and promising efficacy in early phase clinical studies

Mary Hu, Chief Executive Officer, Shanghai Miracogen

11.45 Antibody Drug Conjugate Development: Current Clinical Status & Future Directions

Presenting an update on the key movements in the clinic
Gain insight into the rapidly evolving pipeline
Analyse novel clinical ADCs

Jia He, Senior Research Analyst, Beacon Targeted Therapies

12.15 Delving into Disitamab Vedotin: A Novel HER2 ADC

Disitamab vedotin is a HER2 ADC with an antibody designed to maximise drug delivery with higher affinity and internalisation rate as compared to trastuzumab in preclinical models
Highlighting DV’s encouraging monotherapy clinical data across a range of HER2 expressing solid tumours, and combination activity with anti-PD1 in urothelial cancer

Nicholas Choong, VP, Clinical Development, Seagen

AM: CMC Stream Chair: Lisa McDermott, Director, Process & Analytical Development, Merck

Developing a Strong CDMO Relationship for Effective External Manufacturing

11.15 Streamlining Three ADC Unit Operations: Introducing the Sartoflow Expert SU TFF System

Integrated: Tempered liquid-liquid mixing, sterile-grade filtration and TFF on one skid at ~3-20 litre scale

Assured Safety: Fully automated process control, full chemical resistance and comprehensive risk mitigation concept

Increased Efficiency: Broad member spectrum, maximised drainability and minimum hold-up volume in fully closed TFF loop

Marvin Machava, Process Engineer - Downstream Development, Sartorius

Hannes Landmann, Product Manager Crossflow Systems, Sartorius

11.45 Evaluating Whether to Outsource to One CDMO or Several

Understanding the relative complexity with both options
Discussing planning, legal and sourcing considerations
Ensuring quality and reliability are at the heart of centre of the decision-making process

Christian Lutz, Director, Project Management CMC, Heidelberg Pharma Research

12.15 Looking to Satisfy the Growing Demand of Capacity & Capabilities for ADCs

A quick look to the most recent data to check how the ADCs market is evolving
Discussing drivers and challenges in ADCs’ manufacturing: Outsourcing or In-house?
Assessing the basics of Integration and our model to support ADCs’ needs
Presenting our conjugation and fill/finish capabilities

Giorgio Salciarini, Senior Manager – Technical Business Development, BSP Pharmaceuticals

12:45 pm Lunch & Networking Supported by Proveo

PM: Discovery Stream Chair: Philip Howard, Chief Scientific Officer, Spirogen

Advancing the Next Generation of Payloads to Reach Desired Efficacy

13.45 *Virtual* How Can ADC ExpressTM (actually make that a TM) Help You With Lead Candidate Selection?

Discussing how to speed up linker selection, including solubilizer and functionality
Expedite payload selection
Simplify clone selection

Jeff Carroll, Group Leader Process & Analytical Development, Merck

14.15 Developing PBDs From Natural Products to Zynlonta

Identifying characteristics of the PBD platform
Outlining the Teserine development story
Beyond Zylonta – what are the next PBD ADCs?

Philip Howard, Chief Scientific Officer, Spirogen

14.45 AMDC - Antibody Mimetic Drug Conjugates: Precision Engineered Medicines for Cancer

Cupid-Psyche: a novel and proprietary platform delivering a variety of payloads to multiple tumor associated antigen targets
A system for the rapid in vivo validation of antibody mimetic targeting ligands including affibodies, nanobodies, aptamers, scFv fragments
POC for a novel and proprietary photoimmunotherapy targeted therapeutic

Michael Chansler, VP, Business Development, Savid Therapeutics

PM: Translational Stream Chair: Greg Thurber, Associate Chair & Associate Professor of Chemical Engineering, University of Michigan

Overcoming Critical In Vivo Challenges to Accelerate Through Preclinical Development

13.45 Quantitative Evaluation of Relation Between Antigen Expression & ADC Exposure in Solid Tumours

Preclinical investigation of the effect of target expression level on ADC exposure in cancer cells and tumours using anti-HER2 Trastuzumab-VC-MMAE tool ADC
Evaluate the usage of cell level and in-vivo mechanistic ADC PK model to characterise preclinical data and the establishment of a quantitative relationship between antigen expression level and ADC exposure in a tumour
Understand the importance of target expression assessment for clinical success of ADCs

Sharad Sharma, Principal Scientist, NBEPK Biotherapeutics Discovery Research, Postdoctoral Associate, Boehringer Ingelheim / The State University of New York, Buffalo

14.45 Advancing Nonclinical Development of PBD-Based ADCs

Reviewing Pyrrolobenzadiazepines as warheads for ADCs
Addressing challenges in preclinical development of PBD-based payloads when compared to other payloads
Assessing the clinical dose setting based on nonclinical data

Lolke de Haan, Head, Toxicology, ADC Therapeutics

14.45 Roundtable Discussion - Overcoming Challenges With Preclinical Animal Model Development

This session is an opportunity to discuss current limitations with animal models as part of small learning groups. Topics to be discussed includes; What are the current limitations with preclinical animal models? What is wanted from an animal model? Examining how well animal models translate to humans, and understanding how rigorous animal model studies should be?

PM: Clinical Stream Chair: Heather Van Epps, Director, Research Early-Stage Clinical Programs, Seagen

Optimising Dosing Schedules & Regimens in Human Trials for a Greater Clinical Efficacy

13.45 *Virtual* Sharing Clinical Pharmacology Strategies to Accelerate ADC Clinical Development, a Polivy Case Study

Overview of ADCs and DLBCL
Examining a population pharmacokinetics model based approach to characterise multiple analytes
Discussing the application of integrated quantitative clinical pharmacology strategies to accelerate POLIVY development

Mike Liao, Global Clinical Pharmacology Lead, Oncology & Immunology, Genentech

14.15 Showcasing the Development of DS-7300, a B7-H3-Directed DXd Antibody-Drug Conjugate

Evaluating the pre-clinical profile and mechanism of action of DS-7300
Sharing the clinical development status of DS-7300
Discussing future developments of DS-7300

Gilles Gallant, SVP Global Head, Oncology Development, Oncology R&D, Daiichi Sankyo

14.45 Targeting Folate Receptor-α in Gynecologic Cancers & other Solid Tumours with the Novel Antibody-Drug Conjugate, STRO-002

Review STRO-002 preclinical data (in vitro cytotoxicty and xenograft models) in ovarian, endometrial and other cancers
Evaluate clinical outcomes data from the STRO-002-GM1 dose escalation and expansion cohorts
Investigate ongoing clinical trials testing STRO-002 as a monotherapy and in combination with other agents

Arturo Molina, Chief Medical Officer, Sutro Biopharma

PM: CMC Stream Chair: Lisa McDermott, Director, Process & Analytical Development, Merck

Streamlining Process Development to Confidently Scale-Up Your Manufacturing Capabilities

13.45 Crucial Containment Features & SOP Development for Passing Nanogram Containment Testing Criteria

Studying your testing circumstances and process environment - How risk assessments are necessary to achieve best performance?
Mechanical Criteria vs SOP Development - How can we combine these important features to eliminate risk?
How to trust in experienced partners and how to get the most out of their knowledge base

Declan O’Shea, Product Manager, Isolator and Containment Systems, ILC Dover

14.15 Integration & Acceleration of an ADC Within MSD

Introducing a new modality to an established organisation
Working with external partners to accelerate an accelerated programme
Building knowledge and capabilities across the organisation with a nascent technology

Christopher Gillespie, Director, Biologics R&D, MSD

14.45 Use of Design of Experiments to Define Manufacturing Process Conditions for an ADC

Explore the use of design of experiments (DOE) to understand the impact of process parameters at the reactive stages on an ADC product quality attributes
A 2^4 full factorial design was performed and the results were analysed via the MODDE® software, with Drug to Antibody ratio (DAR) results shown
Review how the software enabled identification of safe manufacturing set points for the process parameters

Conor Barry, Head of Development, Piramal Pharma Solutions

3:15 pm Afternoon Break & Refreshments

Expanding the Horizon for ADC Drug Development

3:45 pm PBD Core Intermediate Expands Broad Payload Product Line to Simplify ADC Payload Development

James Walker Associate Director, Process Chemistry API R&D, Merck

Synopsis

Learn how Merck’s ADCore products can shorten synthetic path to final payload and reduce supply chain complexity
Understand how PBDCore providers excellent flexibility and versatility to produce a variety of clinical PBDs

4:15 pm High-Precision Ambrx ADC Conjugation Process, & Analytical Characterisation to Ensure High Homogeneity & Purity

Mysore Ramprasad Executive Director, Analytical Development & Formulation, Ambrx

Synopsis

*Virtual*

Understanding the Ambrx expanded genetic code, protein expression and site-specific ADC conjugation platform
Investigate the development of platform analytical methods and extended characterisation to demonstrate homogeneity and high product quality
Assess the validation of technology with 3 ADCs

4:45 pm SOT102: Claudin 18.2 Targeting PNU-based ADC for the Treatment of Gastric & Pancreatic Cancer

Radek Spisek Chief Executive Officer, SOTIO

Synopsis

Differentiated ADC targeting CLDN18.2 with novel proprietary antibody
Built on NBE Therapeutics iADC platform: PNU toxin, sortase-mediated coupling
Recruitment of the Phase I trial to start in March 2022

5:15 pm End of Scientific Programme Day One

Scientific Poster Session & Drinks Reception

Synopsis

After the formal presentations have finished, the learning and networking carries on. The Scientific Poster Session is an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships. During this session over 25 scientific posters will be presented from novel linker designs to validation of site specific conjugation technologies and more informative in vivo models.

March 13-16, 2023
London, UK

March 13-16, 2023
London, UK

Day One

Day Two

8:00 am Registration Open

8:50 am Chairperson’s Opening Remarks

Reviewing Recent Breakthroughs & Thinking Strategically About the ADC Landscape

9:00 am Bringing Mirvetuximab Soravtansine, an FR-alpha Directed ADC, to Patients with Ovarian Cancer

Synopsis

9:30 am Industry Leaders Panel Discussion – Reviewing the Last Year & Creating Strategies to Further Develop ADCs Through 2022

Synopsis

10:15 am Structured Networking

Synopsis

12:45 pm Lunch & Networking Supported by Proveo

3:15 pm Afternoon Break & Refreshments

Expanding the Horizon for ADC Drug Development

3:45 pm PBD Core Intermediate Expands Broad Payload Product Line to Simplify ADC Payload Development

Synopsis

4:15 pm High-Precision Ambrx ADC Conjugation Process, & Analytical Characterisation to Ensure High Homogeneity & Purity

Synopsis

4:45 pm SOT102: Claudin 18.2 Targeting PNU-based ADC for the Treatment of Gastric & Pancreatic Cancer

Synopsis

5:15 pm End of Scientific Programme Day One

Scientific Poster Session & Drinks Reception

Synopsis

OUR CONTACT DETAILS

VENUE DETAILS

ABOUT US

LOCATION

SEARCH

March 13-16, 2023 London, UK

March 13-16, 2023 London, UK

Day One

Day Two

8:00 am Registration Open

8:50 am Chairperson’s Opening Remarks

Reviewing Recent Breakthroughs & Thinking Strategically About the ADC Landscape

9:00 am Bringing Mirvetuximab Soravtansine, an FR-alpha Directed ADC, to Patients with Ovarian Cancer

Synopsis

9:30 am Industry Leaders Panel Discussion – Reviewing the Last Year & Creating Strategies to Further Develop ADCs Through 2022

Synopsis

10:15 am Structured Networking

Synopsis

12:45 pm Lunch & Networking Supported by Proveo

3:15 pm Afternoon Break & Refreshments

Expanding the Horizon for ADC Drug Development

3:45 pm PBD Core Intermediate Expands Broad Payload Product Line to Simplify ADC Payload Development

Synopsis

4:15 pm High-Precision Ambrx ADC Conjugation Process, & Analytical Characterisation to Ensure High Homogeneity & Purity

Synopsis

4:45 pm SOT102: Claudin 18.2 Targeting PNU-based ADC for the Treatment of Gastric & Pancreatic Cancer

Synopsis

5:15 pm End of Scientific Programme Day One

Scientific Poster Session & Drinks Reception

Synopsis

OUR CONTACT DETAILS

VENUE DETAILS

ABOUT US

LOCATION

SEARCH

March 13-16, 2023
London, UK

March 13-16, 2023
London, UK